# EDGAR Filing Document

**Accession Number:** 0001876264
**File Stem:** 0001193125-26-059504
**Filing Date:** 2026-2
**Character Count:** 10406
**Document Hash:** 17e2df13a8f472bd1d41b6405e02b6b6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-059504.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0001193125-26-059504

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evommune, Inc.
- **CENTRAL INDEX KEY:** 0002044725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 850742575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95351
- **FILM NUMBER:** 26654903

**BUSINESS ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 223-7745

**MAIL ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LSP 7 Cooperative UA
- **CENTRAL INDEX KEY:** 0001876264

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** JOHANNES VERMEERPLEIN 9
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31206645500

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** JOHANNES VERMEERPLEIN 9
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LSP Cooperative UA
- **DATE OF NAME CHANGE:** 20210802

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Evommune, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**30054Y107**

*(CUSIP Number)*

**Bas Vaessen**<br>LSP 7 Management B.V.<br>Johannes Vermeerplein 9<br>Amsterdam P7 1071 DV<br>31206645500

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/12/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **30054Y107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**LSP 7 Cooperatieve U.A.** | Name of reporting person<br>**LSP 7 Cooperatieve U.A.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5288313.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5288313.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5288313.00** | Aggregate amount beneficially owned by each reporting person<br>**5288313.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**14.7%** | Percent of class represented by amount in Row (11)<br>**14.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **30054Y107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**LSP 7 Management B.V.** | Name of reporting person<br>**LSP 7 Management B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5288313.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5288313.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5288313.00** | Aggregate amount beneficially owned by each reporting person<br>**5288313.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**14.7%** | Percent of class represented by amount in Row (11)<br>**14.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Evommune, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
1841 Page Mill Road, Suite 100, Palo Alto, CA, 94304

Explanatory Note

This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the "SEC") on November 14, 2025 (as amended to date, the "Schedule 13D"), relating to the shares of common stock, $0.0001 par value per share (the "Common Stock"), of Evommune, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The ownership information presented herein represents beneficial ownership of Common Stock as of the date hereof, based on 36,018,372 shares of Common Stock outstanding following the Closing Date.

LSP 7 is the record holder of the shares of Common Stock reported herein and is the beneficial owner of approximately 14.7% of the outstanding shares of Common Stock. LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.

**(b)**
Sole power to vote or to direct the vote: 0

Shared power to vote or to direct the vote: 5,288,313

Sole power to dispose or to direct the disposition of: 0

Shared power to dispose or to direct the disposition of: 5,288,313

**(c)**
Except as set forth in this Amendment No. 1, during the past 60 days, none of the Reporting Persons nor the Related Persons have effected any transactions in the Common Stock.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

Item 3 of the Schedule 13D is incorporated by reference herein.

In connection with the February 2026 Private Placement, the Issuer also entered into a Registration Rights Agreement, dated February 12, 2026 (the "February 2026 Registration Rights Agreement"), with the February 2026 PIPE Investors. Pursuant to the terms of the February 2026 Registration Rights Agreement, the Issuer is obligated to prepare and file with the SEC a registration statement on Form S-1 (the "Registration Statement") to register for resale of the Shares within 60 days of the Closing Date and to use its reasonable best efforts to have the Registration Statement declared effective as soon as possible, but no later than 90 days after the initial filing date of the Registration Statement, subject to extension under the terms of the February 2026 Registration Rights Agreement. The Issuer also agreed to use reasonable best efforts to keep such Registration Statement effective until the earlier of the date the Shares covered by such Registration Statement have been sold or may be resold pursuant to Rule 144 without restriction. The February 2026 Registration Rights Agreement includes customary provisions regarding payment of fees and expenses and indemnification.

The foregoing description of the February 2026 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Form of Registration Rights Agreement, a copy of which is filed as Exhibit 5 hereto and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** LSP 7 Cooperatieve U.A.

**Signature:** By: LSP 7 Management B.V., its sole director, By: /s/ Martijn Kleijwegt

**Name/Title:** Martijn Kleijwegt, Managing Director

**Date:** 02/19/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** LSP 7 Management B.V.

**Signature:** /s/ Martijn Kleijwegt

**Name/Title:** Martijn Kleijwegt, Managing Director

**Date:** 02/19/2026